Calprotectin Citations Archives - Page 2 of 4 - Buhlmann Diagnostics Corp

Category: Calprotectin Citations

Usability of IBDoc- Novel Fecal Calprotectin Home-Based Rapid Test

IBDoc® Citation: Røer MJ., 2019, Usability of IBDoc, a Novel Fecal Calprotectin Home-Based Rapid Test in Clinical Practice, Point of Care: September 2019 - Volume 18 - Issue 3 - p 85–91. doi: 10.1097/POC.0000000000000192 Highlights from this Publication “Clearly, the majority of the IBD patients found the home-based test valuable...” Read Citation Health Canada License: 98903
Continue Reading

Head-to-head comparison of three stool calprotectin tests for home use

IBDoc® Citation: Haisma et al. Head-to-head comparison of three stool calprotectin tests for home use.  Plos ONE. https://doi.org/10.1371/journal.pone.0214751  April 18, 2019 Highlights from this Publication “ …We observed that 119 of 125 IBDoc readings ≥ 500 μg/g were concordant with fCAL results (95%), compared to 35% and 49% for the QuantOnCal—IDK-Calprotectin and CalproSmart—Calprotectin-ALP pairs.…” “The CalproSmart
Continue Reading

Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring

IBDoc® Citation: Wei, S. , Tung, C. et al.  Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring. Intestinal Research 2018;16(4):546-553. DOI: https://doi.org/10.5217/ir.2018.00052 PMID: 30301339 Highlights from this Publication “96% of the patients were satisfied with the home test..." “71% of patients preferred the home test method monitor
Continue Reading

Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis

IBDoc® Citation: Walsh,  A,  Kormilitzin, A et al. Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis—a Prospective Analysis, Journal of Crohn's and Colitis, jjy184, PMID: 30445625   DOI: doi.org/10.1093/ecco-jcc/jjy184  Highlights from this Publication “This is the first prospective study to use validated endoscopic and histologic indices to determine the thresholds of
Continue Reading

IBDoc Canadian User Performance Evaluation

IBDoc® Citation: Alice C Moore, Vivian W Huang, Raymond Bourdages, Richard N Fedorak, Christian Reinhard, Yvette Leung, Brian Bressler, Greg Rosenfeld; IBDoc Canadian User Performance Evaluation, Inflammatory Bowel Diseases, , izy357, DOI: https://doi.org/10.1093/ibd/izy357 PMID: 30535387 Highlights from this Publication "The majority of patients found it easy-to-use and felt that most patients would be able to learn how to
Continue Reading

Ulcerative Colitis Study: Correlation of Faecal Calprotectin with Histological Nancy Index

BÜHLMANN IBDoc®: Walsh, A, Kormilitzin, A. et al. New faecal calprotectin cut-off points for remission and active disease defined by UCEIS and Nancy indices in ulcerative colitis (UC).  13th Congress of ECCO 2018, Feb 14 – 17, 2018. Vienna, Austria. Highlights from this Poster “Conclusions. An FCal <180 g/g is indicative of endoscopic and histological remission. FCal
Continue Reading

Home-based Fecal Calprotectin Testing: A Canadian User Performance Evaluation Study of IBDoc®

BÜHLMANN IBDoc®: Wong, A, Bourdages, R. et al. Home-based Fecal Calprotectin Testing: A Canadian User Performance Evaluation Study of IBDoc®.  CDDW 2018, Feb 09 – 11, 2018. Toronto, ON Canada. Highlights from this Publication “Conclusions. The IBDoc® test kit was understood by participants, with a majority of participants finding it easy to use, with an
Continue Reading

Fecal Calprotectin Measurement is a Marker of Short-Term Clinical Outcome and Presence of Mucosal Healing in Patients with Inflammatory Bowel Disease

BÜHLMANN fCAL® ELISA: A.Kostas, S.I. Siakavellas, et al. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. World Journal of Gastroenterology; November 2017. PMID: 29151692 DOI: 10.3748/wjg.v23.i41.7387. Highlights from this Publication “In our patient cohort, we were able to define an optimal cut-off FC value of 261 µg/g, which had a
Continue Reading

Fecal Calprotectin in Healthy Children Aged 1-4 Years

BÜHLMANN fCAL® ELISA Citation: Zhu, Q,Feng Li, Junli Wang, Lixiao Shen, Xiaoyang Sheng. Fecal Calprotectin in Healthy Children Aged 1-4 Years, PLOS ONE. 2016. http://dx.doi.org/10.1371/journal.pone.0150725.

Highlight from this Publication:

“Children aged from 1 to 4 years old have lower FC concentrations compared with healthy infants (<1years), and higher FC concentrations when comparing with children older than 4 years and adults.”
Continue Reading

Comparison of Three Tests for Faecal Calprotectin in Children and Young Adults: a Retrospective Monocentric Study

BÜHLMANN fCAL® ELISA Citation: Prell, C, Nagel D, Freudenberg H, Schwarzer A, Koletzko S. Comparison of three tests for faecal calprotectin in children and young adults: a retrospective monocentric study, BMJ Open. 2014;4:e004558 doi:10.1136/bmjopen-2013-004558.

Highlights from this Publication

“In conclusion, measurement of FC in paediatric patients with unspecific symptoms is very helpful in order to avoid invasive procedure.”
Continue Reading